Meta-analyses and studies in population-based cohorts have supported the efficacy of plasma p-tau biomarkers, particularly p-tau217, in predicting the transition from mild cognitive impairment to dementia, even when considering other risk factors [100,101]. This evidence concerns the gene MAPT and dementia.